sutimlimab

FDA Drug Profile

Drug Details

Generic Name
sutimlimab
Brand Names
N/A
Application Number
Sponsor
Biogen Inc.
NDC Codes
1
Dosage Forms
LIQUID
Routes
N/A
Active Ingredients
SUTIMLIMAB

Indications and Usage

1 INDICATIONS AND USAGE ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).